Shenzhen Zhongge Biotechnology Co. Ltd. has described kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer and fibrosis.

Genescience Pharmaceuticals Co. Ltd. has identified phenylalanine hydroxylase (PAH) (R408W mutant) stabilizers reported to be useful for the treatment of phenylketonuria (PKU).

Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.

Bioage Labs Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammatory disorders.

Researchers at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have described oxazole derivatives acting as malate dehydrogenase, cytoplasmic (MDH1) and/or malate dehydrogenase, mitochondrial (MDH2) inhibitors reported to be useful for the treatment of cancer.

Scientists at Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have divulged histone acetyltransferase KAT6A (MOZ; MYST-3) and histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of breast cancer.

Pyrotech (Beijing) Biotechnology Co. Ltd. has identified gasdermin-E (GSDME) inhibitors reported to be useful for the treatment of genetic diseases, cancer, viral infection, age-related macular degeneration, autoimmune diseases, neurological disorders, renal disorders and cancer therapy-associated disorders.

Suzhou Puhe Biopharma Co. Ltd. has synthesized GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Nuphase Therapeutics (Shanghai) Co. Ltd. has disclosed compounds acting as interleukin-17A/A homodimer and IL-17A/F heterodimer inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory diseases.